Whitehouse Scientific’s managing director, Jamie Storey, showed his support for ‘Movember’ by joining more than 850,000 fellow ‘Mo Bros’ from around the world in growing facial hair throughout the month of November.
From humble beginnings, ‘Movember’ has become a global campaign aimed at raising vital funds and awareness for men’s health, specifically prostate and testicular cancer. It is one of a number of charity initiatives supported by the Whitehouse Scientific team.
‘Although I have spent the month looking a bit of a fool it was worth it for such a great cause,’ said Storey.
‘With awareness being the key, it was a pleasure explaining why I had grown a handlebar moustache to the many who have asked. I look forward to trying out a new style next year.’
Funds raised by ‘Movember’ in the UK are directed to The Prostate Cancer Charity and Institute of Cancer Research, which supports programmes aimed at increasing early cancer detection, diagnosis and effective treatments, and ultimately reducing the number of preventable deaths.
To date, ‘Movember’ has raised nearly £65m, with £15m coming from the UK. A total of £170m has been collected since 2004.
Whitehouse md grows moustache for charity
Joins fellow ‘Mo Bros’ around the world to raise funds and awareness for men’s health
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development